Liminal BioSciences Inc. (LMNL)
| Market Cap | 129.63M |
| Revenue (ttm) | 2.60M |
| Net Income (ttm) | -93.80M |
| Shares Out | 29.94M |
| EPS (ttm) | -3.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $4.15 |
| Previous Close | $4.23 |
| Change ($) | -0.08 |
| Change (%) | -1.89% |
| Day's Open | 4.26 |
| Day's Range | 3.53 - 4.40 |
| Day's Volume | 755,155 |
| 52-Week Range | 3.51 - 31.45 |
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of -8.77% and 52.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Initiated Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras OXER1 Antagonist Preclinical R&D Program Acquired Changes to Board of Directors & Executive Team US$30M in gross proceeds from a pr...
Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announ...
Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript
LAVAL, QC and CAMBRIDGE, England, Nov. 13, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced tha...
LAVAL, QC and CAMBRIDGE, England, Nov. 10, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announc...
PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th LAVAL, QC, and CAMBRIDGE, England, Nov. 8, 2020 /PRNewswire/ - Liminal BioSciences In...
LAVAL, QC and CAMBRIDGE, England, Nov. 6, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announce...
LAVAL, QC and CAMBRIDGE, England, Nov. 5, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announce...
- FDA assigns PDUFA target action date of March 5, 2021 LAVAL, QC and CAMBRIDGE, England, Sept. 21, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), ...
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s o...
Liminal BioSciences: Under New Management And Chasing Ryplazim Approval
LAVAL, QC, and CAMBRIDGE, England, Aug. 6, 2020 /PRNewswire/ - Liminal BioSciences Inc.
Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.
LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, to...
LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, t...
LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, t...
LAVAL, QC and CAMBRIDGE, United Kingdom, June 11, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical com...
LAVAL, QC, and CAMBRIDGE, United Kingdom, May 28, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical com...
About LMNL
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of i... [Read more...]
| Industry Biotechnology | |
| CEO Kenneth Galbraith | Employees 251 |
| Stock Exchange NASDAQ | Ticker Symbol LMNL |
Financial Performance
In 2020, LMNL's revenue was 3.32 million, a decrease of -32.36% compared to the previous year's 4.90 million. Losses were -119.59 million, -42.45% less than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for LMNL stock is "Buy." The 12-month stock price forecast is 10.06, which is an increase of 142.41% from the latest price.